Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zika Virus CHIM Evaluation
NCT05123222Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZIKV-SJRP/2016-184 in Zika virus infection (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Solicited Adverse Events, Severity of Adverse Events and 4 more. Started Feb 2022; status: completed.
02
Drugs
ZIKV-SJRP/2016-184
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT05123222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05123222.